Salomon Azoulay sold $2.7M of MBX
Chief Medical Officer at MBX Biosciences, Inc.. 70,003 shares at an average of $38.36, traded May 8, 2026, filed May 11, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.7M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -22.7%, 3m +65.0%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-216704, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2026 | MOption exercise Common Stock10b5-1 | +55,000 | $10.46 | $575k | 69,769 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -55,000 | $38.38 | $2.1M | 14,769 | May 11, 2026 |
| May 8, 2026 | MOption exercise Common Stock10b5-1 | +15,003 | $16.00 | $240k | 29,772 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -15,003 | $38.30 | $575k | 14,769 | May 11, 2026 |
| May 8, 2026 | MOption exercise Stock option (right to buy)derivative10b5-1 | +55,000 | $0.00 | $0 | 194,540 | May 11, 2026 |
| May 8, 2026 | MOption exercise Stock option (right to buy)derivative10b5-1 | +15,003 | $0.00 | $0 | 30,008 | May 11, 2026 |
Related signals
Other insiders at MBX Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | MBXsell MBX Biosciences, Inc. | Salomon Azoulay Chief Medical Officer | $24k 370 shares | -3% | |
| 23Weak | MBX Biosciences, Inc. | Salomon Azoulay Chief Medical Officer | $6,824 231 shares | -2% | |
| 33Weak | MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $18k 607 shares | -0% | |
| 51Moderate | MBXbuy MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $526k 18,500 shares | +4% | |
| 54Moderate | MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $273k 20,000 shares | +4% | |
| 52Moderate | MBX Biosciences, Inc. | Steven L. Hoerter President and CEO | $265k 20,000 shares | - | |
| 51Moderate | MBXbuy MBX Biosciences, Inc. | Patrick J Heron director, owner | $12M 666,666 shares | +15% | |
| 45Moderate | MBXbuy MBX Biosciences, Inc. | Ora H. Pescovitz director | $45k 7,693 shares | +46% | |
| 51Moderate | MBX Biosciences, Inc. | Carl L Gordon director, owner | $2.0M 190,672 shares | +6% | |
| 54Moderate | MBX Biosciences, Inc. | P. Kent Hawryluk President & CEO | $535k 50,000 shares | +13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.